Engineered cells take aim at tough autoimmune diseases

NCT ID NCT06925542

First seen Oct 31, 2025 · Last updated May 12, 2026 · Updated 22 times

Summary

This early-stage study tests a new treatment called CTX112 for people with severe autoimmune diseases like lupus, scleroderma, or myositis that haven't improved with standard therapies. CTX112 uses specially engineered immune cells from a donor to target and attack faulty immune cells causing the disease. The main goal is to check safety, but researchers will also look for signs that the treatment is working.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site 1

    RECRUITING

    St Louis, Missouri, 63130, United States

  • Research Site 2

    RECRUITING

    Chicago, Illinois, 63110, United States

  • Research Site 3

    RECRUITING

    Hanover, 30625, Germany

  • Research Site 4

    RECRUITING

    Redwood City, California, 94063, United States

  • Research Site 5

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • Research Site 6

    RECRUITING

    Boston, Massachusetts, 02118, United States

  • Research Site 7

    NOT_YET_RECRUITING

    Augsburg, 86156, Germany

  • Research Site 8

    RECRUITING

    Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.